ASLAN Pharma: Gains on approval to expand eczema treatment study

Aslan Pharmaceuticals

11/01/2021 15:04

** U.S.-listed shares of Singapore-based drug developer
 ASLN.O  rise 1.2% to $2.01
    ** Co receives approval from Data Monitoring Committee to
begin patient recruitment for final cohort of an early-stage
dose-escalating study of its experimental treatment ASLAN004 for
atopic dermatitis (https://refini.tv/3sgbIsv)
    ** Atopic dermatitis is a condition that makes skin red and
itchy
    ** Plans to recruit at least 18 patients in new expanded
cohort
    ** ASLN plans to report data from first three dose cohorts
as planned in early 2021, followed by data from expansion cohort
in mid-2021
    ** Up to Friday's close, stock down ~6% in last 12 months

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))